BR9407790A - Benzotiofenos e compostos correlatos como agonistas de estrogênio - Google Patents

Benzotiofenos e compostos correlatos como agonistas de estrogênio

Info

Publication number
BR9407790A
BR9407790A BR9407790A BR9407790A BR9407790A BR 9407790 A BR9407790 A BR 9407790A BR 9407790 A BR9407790 A BR 9407790A BR 9407790 A BR9407790 A BR 9407790A BR 9407790 A BR9407790 A BR 9407790A
Authority
BR
Brazil
Prior art keywords
benzothiophenes
related compounds
estrogen agonists
estrogen
agonists
Prior art date
Application number
BR9407790A
Other languages
English (en)
Inventor
Kimberly O Cameron
Silva-Jardine Paul Da
Eric R Larson
James R Hauske
Robert L Rosati
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22467873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9407790(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR9407790A publication Critical patent/BR9407790A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR9407790A 1993-10-12 1994-09-19 Benzotiofenos e compostos correlatos como agonistas de estrogênio BR9407790A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13538693A 1993-10-12 1993-10-12
PCT/IB1994/000282 WO1995010513A1 (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists

Publications (1)

Publication Number Publication Date
BR9407790A true BR9407790A (pt) 1997-03-18

Family

ID=22467873

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407790A BR9407790A (pt) 1993-10-12 1994-09-19 Benzotiofenos e compostos correlatos como agonistas de estrogênio

Country Status (19)

Country Link
US (1) US6756388B1 (pt)
EP (1) EP0723537A1 (pt)
JP (1) JPH08511273A (pt)
KR (1) KR960704874A (pt)
CN (1) CN1133040A (pt)
AU (1) AU7545394A (pt)
BR (1) BR9407790A (pt)
CA (1) CA2173243A1 (pt)
CO (1) CO4290353A1 (pt)
CZ (1) CZ105696A3 (pt)
FI (1) FI944771A7 (pt)
HU (1) HUT75231A (pt)
IL (1) IL111187A0 (pt)
NO (1) NO961432L (pt)
NZ (1) NZ271733A (pt)
PE (1) PE22095A1 (pt)
PL (1) PL313905A1 (pt)
WO (1) WO1995010513A1 (pt)
ZA (1) ZA947911B (pt)

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US6399634B1 (en) * 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6703407B1 (en) * 1994-09-20 2004-03-09 Eli Lilly And Company Benzofuran compounds, compositions, and methods
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5977093A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5998401A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5622974A (en) * 1995-03-10 1997-04-22 Eli Lilly And Company α-substituted-3-benzyl-benzofurans
US6451817B1 (en) 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6395755B1 (en) * 1995-03-10 2002-05-28 Eli Lilly And Company Benzothiophene pharmaceutical compounds
US6653328B1 (en) 1995-03-10 2003-11-25 Eli Lilly And Company 3-benzyl-benzothiophenes
US6391892B1 (en) * 1995-03-10 2002-05-21 Eli Lilly And Company Naphthyl pharmaceutical compounds
US6384053B1 (en) 1995-03-10 2002-05-07 Eli Lilly And Company α-substituted-1-benzyl-napthyls
US5705507A (en) * 1995-03-10 1998-01-06 Eli Lilly And Company Aplha-substituted-3-benzyl-benzofurans
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US6608090B1 (en) 1995-04-21 2003-08-19 Eli Lilly And Company Benzothiophenes with novel basic side chains
JPH11504013A (ja) * 1995-04-21 1999-04-06 イーライ・リリー・アンド・カンパニー 新規な塩基性側鎖を有するベンゾチオフェン
US6444688B1 (en) * 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US5567828A (en) * 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
US6440958B1 (en) 1995-06-26 2002-08-27 Eli Lilly And Company Acrylic and propionic acid compounds, intermediates, processes, compositions, and methods
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
EP0863755B1 (en) 1995-10-31 2004-12-15 Eli Lilly And Company Antithrombotic diamines
JP3092946B2 (ja) * 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤
US6432982B1 (en) * 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
WO1997030709A1 (en) * 1996-02-22 1997-08-28 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
DE19609827A1 (de) * 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
WO1997034888A1 (en) * 1996-03-19 1997-09-25 Eli Lilly And Company SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
US6147088A (en) * 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6350884B1 (en) 1996-06-25 2002-02-26 Eli Lilly And Company Acrylic and propionic acid compounds, intermediates, processes, compositions, and method
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
CA2207083A1 (en) * 1996-07-15 1998-01-15 Brian William Grinnell Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
BR9713176A (pt) * 1996-08-28 2000-02-08 Lilly Co Eli Benzotiofenos amorfos,métodos de preparação e métodos de uso
CA2214070C (en) * 1996-08-29 2006-03-14 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US6599920B2 (en) 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
ID19392A (id) 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213810C (en) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods
CA2214919A1 (en) * 1996-09-24 1998-03-24 Kenneth Lee Hauser Benzothiophene compounds, intermediates, processes, compositions, and methods
MY118009A (en) * 1996-09-25 2004-08-30 Lilly Co Eli Process for the synthesis of benzothiophenes
CA2214935A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Benzofluorene compounds, intermediates, compositions, and methods
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
CA2215856A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions, and methods
CA2214196A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Benzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods
CA2214176A1 (en) * 1996-09-26 1998-03-26 Eli Lilly And Company Dihydrobenzo[b]indeno[2,1-d]thiophene compounds, intermediates, processes, compositions and methods
CA2214922A1 (en) * 1996-09-27 1998-03-27 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
JPH10130258A (ja) * 1996-10-10 1998-05-19 Eli Lilly & Co ベンゾ[b]チオフェン化合物、中間体、製剤、および方法
US5948796A (en) * 1996-10-10 1999-09-07 Eli Lilly And Company Benzo B!thiophene compounds, intermediates, formulations, and methods
US5958969A (en) * 1996-10-10 1999-09-28 Eli Lilly And Company Benzo b!thiophene compounds, intermediates, formulations, and methods
US5939444A (en) * 1996-10-23 1999-08-17 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5965573A (en) * 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5922753A (en) * 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
CA2216592C (en) * 1996-10-24 2006-07-18 Brian Stephen Muehl Benzothiophene compounds, intermediates, compositions, and methods
CA2214872C (en) * 1996-10-24 2002-01-22 Eli Lilly And Company Benzothiophene compounds, compositions and methods
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物
US6034102A (en) 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
AU7467398A (en) * 1997-04-25 1998-11-24 Eli Lilly And Company Indene compounds having activity as serms
EP0980367A4 (en) 1997-04-30 2003-03-19 Lilly Co Eli ANTITHROMBOTIC AGENTS
EP0980366B1 (en) 1997-04-30 2004-06-09 Eli Lilly And Company Antithrombotic agents
EP0973517A4 (en) 1997-04-30 2002-07-24 Lilly Co Eli ANTITHROMBOTIC AGENTS
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
CA2288224A1 (en) 1997-04-30 1998-11-05 Mary George Johnson Antithrombotic agents
JP2001523253A (ja) * 1997-04-30 2001-11-20 イーライ・リリー・アンド・カンパニー ベンゾ[b]チオフェン類の製造のための中間体および方法
CA2287918A1 (en) * 1997-04-30 1998-11-05 John Mcneill Mcgill Iii A regioselective alkylation process for preparing substituted benzo¬b|thiophenes
JP2001524114A (ja) * 1997-04-30 2001-11-27 イーライ・リリー・アンド・カンパニー ベンゾ[b]チオフェン類の製造における中間体および方法
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
KR20010020378A (ko) * 1997-04-30 2001-03-15 피터 지. 스트링거 벤조티오펜의 제조 방법
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
JP2002506433A (ja) * 1997-06-10 2002-02-26 カロ バイオ アクチェブラーグ エストロゲン・レセプター・リガンド
US5760030A (en) * 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
CA2298651A1 (en) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
JP2001519349A (ja) 1997-10-03 2001-10-23 イーライ・リリー・アンド・カンパニー ベンゾチオフェン
BR9812944A (pt) 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
WO1999054325A1 (en) * 1998-04-17 1999-10-28 Senga Pharmaceutical Laboratory Inc. 1-heteroindene derivatives and medicinal composition containing the same
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
WO2000021951A1 (en) 1998-10-08 2000-04-20 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9822945D0 (en) * 1998-10-20 1998-12-16 Isis Innovations Ltd Epibatidine analogues
PT997460E (pt) * 1998-10-28 2003-03-31 Lilly Co Eli Compostos benzotiofenos como agentes antitromboticos e seus intermediarios
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
AU5878001A (en) * 2000-05-18 2001-11-26 Daiichi Pharmaceutical Co., Ltd. Novel benzothiophene derivatives
FR2813306B1 (fr) 2000-08-23 2005-10-21 Sanofi Synthelabo Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
FR2813308B1 (fr) 2000-08-23 2005-07-01 Sanofi Synthelabo Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant
FR2813307B1 (fr) * 2000-08-23 2002-11-08 Sanofi Synthelabo Aminoalkenylbenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US20060235061A1 (en) * 2002-06-21 2006-10-19 Qlt,Inc. Methods of using benzothiophenone derivatives to treat cancer or inflammation
EA008024B1 (ru) 2002-07-22 2007-02-27 Эли Лилли Энд Компани Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу
DE60333112D1 (de) 2002-08-02 2010-08-05 Univ Ohio State Res Found 2-heterosubstituierte 3-aryl-4-h-1-benzopyran-4-one als neue therapeutika bei brustkrebs
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
EP1416028A1 (en) * 2002-10-30 2004-05-06 Covion Organic Semiconductors GmbH New method for the production of monomers useful in the manufacture of semiconductive polymers
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509170A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
EP1569900B1 (en) 2002-12-10 2006-06-28 Wyeth Substituted 3-carbonyl-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005000834A1 (en) * 2003-06-10 2005-01-06 Eli Lilly And Company Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
WO2005073206A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂-1的噻唑基-萘基酸
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
AP2007003979A0 (en) 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
CN101111491A (zh) 2005-01-27 2008-01-23 惠氏公司 用于制备被取代的萘基吲哚衍生物的方法和化合物
JP4761112B2 (ja) * 2005-02-16 2011-08-31 公益財団法人新産業創造研究機構 ベンゾフラン誘導体を含有してなる、骨代謝疾患を予防または治療するための組成物
GR1005694B (el) * 2005-06-08 2007-10-22 Αλεξης Μιχαηλ Ιστοειδικα αντιοιστρογονα ειδικα για τον αλφα υποδοχεα των οιστρογονων
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
WO2006136837A2 (en) 2005-06-23 2006-12-28 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
BRPI0614340A2 (pt) 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
BRPI0818637A2 (pt) 2007-10-16 2015-04-07 Repros Therapeutics Inc Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
CN102264733B (zh) 2008-10-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体,其制备方法及其医药用途
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CA2769038A1 (en) 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2011029088A2 (en) * 2009-09-07 2011-03-10 Dr. Reddy's Laboratories Ltd. Preparation of raloxifene and its salts
EP2314581B1 (en) * 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
JP2015508825A (ja) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド アンドロゲン欠乏症を治療するための併用療法
EP2912033A4 (en) * 2012-10-24 2016-09-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES
ES2774935T3 (es) 2012-10-24 2020-07-23 Univ Illinois Composiciones y métodos para tratar trastornos médicos relacionados con estrógeno
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
TW202000205A (zh) 2018-02-21 2020-01-01 美商Ai治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CN112424205B (zh) * 2018-07-12 2023-10-31 伊莱利利公司 选择性的雌激素受体降解剂
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
CN116813603B (zh) * 2023-06-02 2024-10-22 成都市第三人民医院 一种选择性雌激素受体α降解化合物及其制备方法和应用
WO2025000051A1 (en) 2023-06-28 2025-01-02 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
GB2097788B (en) * 1981-04-03 1985-04-24 Lilly Co Eli Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CZ105696A3 (en) 1997-01-15
FI944771L (fi) 1995-04-13
NZ271733A (en) 1997-11-24
AU7545394A (en) 1995-05-04
PE22095A1 (es) 1995-08-15
US6756388B1 (en) 2004-06-29
NO961432D0 (no) 1996-04-11
NO961432L (no) 1996-04-11
KR960704874A (ko) 1996-10-09
EP0723537A1 (en) 1996-07-31
HUT75231A (en) 1997-04-28
WO1995010513A1 (en) 1995-04-20
FI944771A0 (fi) 1994-10-11
CN1133040A (zh) 1996-10-09
HU9600947D0 (en) 1996-06-28
IL111187A0 (en) 1994-12-29
JPH08511273A (ja) 1996-11-26
ZA947911B (en) 1996-04-11
PL313905A1 (en) 1996-08-05
CO4290353A1 (es) 1996-04-17
FI944771A7 (fi) 1995-04-13
CA2173243A1 (en) 1995-04-20

Similar Documents

Publication Publication Date Title
BR9407790A (pt) Benzotiofenos e compostos correlatos como agonistas de estrogênio
NO971257L (no) Sikt
IS1788B (is) Andestrogen benzothiophenyl efnasambönd
DE69434601D1 (de) Markierung als Bezugspunkt
DE69728356D1 (de) Vernetzbare Zusammensetzung
BR9407549A (pt) Absorvente feminino
DE59510622D1 (de) Substituierte diazacyclohexandi(thi)one
DE69400835D1 (de) Verschmutzungsverhindernde Substanz
FI942234A0 (fi) Seulontasylinteri
FI942863A0 (fi) Rf-suoja
DE69731046D1 (de) Sicherheitsbehälter
DE69505888D1 (de) Zeitungspapier
ATE249433T1 (de) Pyrrolidinyl- und pyrrolinyl-äthylamin- verbindungen als kappa-agonisten
FI943744A0 (fi) Hopfaellbart staell foer baerbar mikrodator i bil
PT807946E (pt) Disjuntor de alta tensao com auto-sopragem
FI963863L (fi) Analyyttinen toteaminen
BR9509899A (pt) Composição modificadora de sabor
FR2769234B1 (fr) Composition de decontamination
DE69708612D1 (de) Matrix-indexierung
FI963862A7 (fi) Analyyttinen ilmaiseminen
DE69713958D1 (de) Zirkulator
ID21978A (id) Sintesa benzo (f) kinolinon
ID18767A (id) Kontainer corong tuang
KR950001897U (ko) 시료 채취기
DE69406402D1 (de) Zwischenspeicher

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal